북미 전체 엑솜 시퀀싱 시장 – 2030년까지의 산업 동향 및 예측

북미 전체 엑솜 시퀀싱 시장 분석 및 통찰력

저렴한 시퀀싱 능력으로 인해 전체 게놈 시퀀싱보다 WES의 선호도가 높아지는 것이 예측 기간 동안 시장 성장을 주도하는 주요 요인입니다. 그러나 높은 장비 비용, 숙련된 전문가에 대한 필요성, 보조금 및 기금에 대한 높은 의존도는 전체 엑솜 시퀀싱 시장의 미래 성장을 방해할 수 있습니다. 주요 시장 참여자의 파트너십 및 인수와 같은 전략적 제휴 채택은 전체 엑솜 시퀀싱 시장 성장의 기회로 작용합니다.

전체 엑솜 시퀀싱 시장은 2023년에서 2030년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2023년에서 2030년의 예측 기간 동안 22.0%의 CAGR로 성장하고 있으며 2022년의 4억 3,597만 달러에서 2030년까지 2,192.73만 달러에 도달할 것으로 분석합니다.

시장 정의

Whole exome is a genomic technique for sequencing all of the protein-coding region of genes in a genome. Whole exome sequencing (WES) is available to patients who are searching for a unifying diagnosis for multiple medical conditions. A laboratory process that is used to determine the nucleotide sequence primarily of the exonic (or protein-coding) regions of an individual’s genome and related sequences, representing approximately 1% of the complete DNA sequence, called WES. Whole-exome sequencing is a widely used whole exome sequencing (WES) method that involves sequencing the protein-coding regions of the genome. The human exome represents less than 2% of the genome, but contains ~85% of known disease-related variants, 1 making this method a cost-effective alternative to whole-genome sequencing

North America Whole Exome Sequencing Market Dynamics

Drivers

• Increasing Diagnostics Applications of Whole Exome Sequencing

There are over 7,000 identified rare diseases and approximately 80% are linked to genetic causes, diagnosing rare disease patients can often be challenging – resulting in lengthy, expensive, and emotional diagnostic odysseys.

Hence, diagnostic applications of WES is expected to propel the market size and is expected to act as driver for the global whole exome sequencing market in the forecast period.

• Growing Usage of Targeted Sequencing Methods

Next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors as genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer.

NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. The need to order multiple tests to identify the causative mutation is eliminated because NGS can assess multiple genes in a single assay.

Opportunity

• Increasing Product Launch in Recent Years

Market players are focusing on launch of new products in whole exome sequencing due to increasing demand for whole exome sequencing techniques. Advancement in the technology is helping the market players for multiple launches of products.

The product launches in the recent years have shown the potential of this technologies and the companies working on this market are trying to get more advanced product in the market which will act as opportunity for the market and will propel the market in forecast period.

Challenges/ Restraints

• Cyber Security Concern in Genomics

Software is known to contain vulnerabilities caused by imperfect code, misconfiguration among other and NGS-related software, used to operate sequencing and laboratory equipment or carry out the bioinformatics analyses, is no exception. Software vulnerabilities are exploited to gain unauthorised access to computer systems or networks, leak data, crash or otherwise disrupt various services.

These types of incidences about data breach and cyber threat associated with the whole exome sequencing is expected to impede the market growth in the forecast period.

• Lack of skilled professionals

The interpretation of whole-exome sequencing (WES) data requires expertise in genomic informatics and clinical medicine to ensure the accurate and safe reporting of findings. The first step of WES involves the acquisition of high-quality genomic DNA (gDNA) from biological samples, most commonly extracted from peripheral blood leukocytes. Professionals should have information about extraction of gDNA. In addition, the preparation of an exome enrichment library is required in WES which is not known to many healthcare specialists.

The professionals are lacking skills are not suitable for performing whole exome sequencing as the diagnostic samples of patients are of keen importance. The need for skilled healthcare has increased. Thus, the lack of skilled professionals to perform whole exome sequencing acts as challenge for the growth of the market.

Recent Development

• In March, Thermo Fisher Scientific launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated, next-generation sequencing (NGS) platform that delivers results in a single day. It is designed for use in clinical laboratories, the fully validated system enables users to perform both diagnostic testing and clinical research on a single instrument. This has helped the company to make advancements in its product portfolio

North America Whole Exome Sequencing Scope and Market Size

North America whole exome sequencing market is segmented on the basis of component, product and service, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Component

• Whole Exome Sequencing
• Third-Generation Sequencing

On the basis of component, the North America whole exome sequencing market is segmented into whole exome sequencing and third-generation sequencing.

Product And Services

• Systems
• Kits
• Services

On the basis of product and service, the North America whole exome sequencing market is segmented into systems, kits, and services.

Application

• Diagnostics
• Drug Discovery and Development
• Personalized Medicine
• Agriculture & Animal Research
• Others

On the basis of application, the North America whole exome sequencing market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine, and others.

End User

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Clinical Laboratories
• Others

On the basis of end user, the North America whole exome sequencing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others.

Distribution Channel

• Direct Trade
• Retail sales
• Others

On the basis of distribution channel, the North America n whole exome sequencing (WES) market is segmented into direct trade, retail sales, and others.

North America Whole Exome Sequencing Market Regional Level Analysis

The whole exome sequencing market is analyzed and market size information is provided by component, product and service, application, end user, and distribution channel.

The countries covered in the whole exome sequencing (WES) market report are the U.S., Canada, Mexico.

U.S. is expected to dominate the market due to the presence of key market players along the largest consumer market with high GDP. U.S. is expected to grow due to rise in technological advancement.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Whole Exome Sequencing Market Share Analysis

Whole exome sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the market.

북미 전체 엑솜 시퀀싱 시장에서 활동하는 주요 기업으로는 Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx(Bio-Techne의 일부), FOUNDATION MEDICINE, INC.(F. Hoffmann-La Roche Ltd의 자회사), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta US Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics(PerkinElmer Inc.의 자회사), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc. 등이 있습니다.

SKU-68566